Literature DB >> 22105112

N-terminal pro-B-type natriuretic peptide and long-term mortality in non-ischaemic cardiomyopathy.

Florian Krackhardt1, Hans-Dirk Düngen, Tobias Daniel Trippel, Simone Inkrot, Verena Tscholl, Peter Schlattmann, Kathrin Kehrt, Wilhelm Haverkamp.   

Abstract

AIM: The inactive N-terminal fragment of B-type natriuretic peptide is a strong predictor of mortality among patients with acute and chronic heart failure secondary to ischaemic heart disease. Its prognostic utility in patients with non-ischaemic heart disease is not well established. We therefore assessed the relationship of N-terminal proBNP levels and long-term mortality in patients with non-ischaemic cardiomyopathy.
METHODS: N-terminal proBNP was measured in serum samples of 156 patients who presented to a single academic centre with worsening heart failure secondary to non-ischaemic cardiomyopathy. The rate of death from all causes was determined after a mean follow-up of 8.9 years.
RESULTS: Multivariate analyses, using Cox proportional hazards models, established NT-proBNP and left ventricular diastolic diameter as predictors for cardiac mortality with estimated hazard ratios of 2.76 (95% confidence interval: 1.53, 4.98) and 1.06 (95% confidence interval: 1.02, 1.10), respectively.
CONCLUSION: This to date longest-term analysis of N-terminal proBNP and mortality in patients with proven non-ischaemic cardiomyopathy confirms this cardiac-specific biomarker as powerful, independent risk predictor. It is a superior prognostic determinant to New York Heart Association functional class and left ventricular ejection fraction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105112     DOI: 10.1007/s00508-011-0092-y

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  23 in total

1.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Authors:  Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

2.  Risk stratification in chronic heart failure: independent and incremental prognostic value of echocardiography and brain natriuretic peptide and its N-terminal fragment.

Authors:  Christian Bruch; Markus Rothenburger; Michael Gotzmann; Juergen Sindermann; Hans H Scheld; Günter Breithardt; Thomas Wichter
Journal:  J Am Soc Echocardiogr       Date:  2006-05       Impact factor: 5.251

3.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.

Authors:  K D Aaronson; J S Schwartz; T M Chen; K L Wong; J E Goin; D M Mancini
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

4.  A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin.

Authors:  Eric Stanton; Mark Hansen; Hairinda C Wijeysundera; Peter Kupchak; Christian Hall; Jean L Rouleau
Journal:  Eur J Heart Fail       Date:  2005-06       Impact factor: 15.534

5.  Survival of patients with a new diagnosis of heart failure: a population based study.

Authors:  M R Cowie; D A Wood; A J Coats; S G Thompson; V Suresh; P A Poole-Wilson; G C Sutton
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

Review 6.  State of the art: using natriuretic peptide levels in clinical practice.

Authors:  Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2008-08-29       Impact factor: 15.534

7.  Predicting mortality in patients with heart failure: a pragmatic approach.

Authors:  M L Bouvy; E R Heerdink; H G M Leufkens; A W Hoes
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

Review 8.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

9.  Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.

Authors:  Lars G Olsson; Karl Swedberg; John G F Cleland; Phillip A Spark; Michel Komajda; Marco Metra; Christian Torp-Pedersen; Willem J Remme; Armin Scherhag; Philip Poole-Wilson
Journal:  Eur J Heart Fail       Date:  2007-08       Impact factor: 15.534

10.  Epidemiology of idiopathic dilated cardiomyopathy in the elderly: pooled results from two case-control studies.

Authors:  S S Coughlin; M C Tefft; J C Rice; J L Gerone; K L Baughman
Journal:  Am J Epidemiol       Date:  1996-05-01       Impact factor: 4.897

View more
  3 in total

Review 1.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 2.  B-type natriuretic peptide-guided treatment for heart failure.

Authors:  Julie McLellan; Carl J Heneghan; Rafael Perera; Alison M Clements; Paul P Glasziou; Karen E Kearley; Nicola Pidduck; Nia W Roberts; Sally Tyndel; F Lucy Wright; Clare Bankhead
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

Review 3.  Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies.

Authors:  Peter McGranaghan; Jennifer A Kirwan; Mariel A Garcia-Rivera; Burkert Pieske; Frank Edelmann; Florian Blaschke; Sandeep Appunni; Anshul Saxena; Muni Rubens; Emir Veledar; Tobias Daniel Trippel
Journal:  Metabolites       Date:  2021-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.